Search Result

Pathways Recommended:	Antibody-drug Conjugate/ADC Related

Results for "

ADC

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (28) ADC Cytotoxin (149) ADC Linker (856) Drug-Linker Conjugates for ADC (269) Acetyl-CoA Carboxylase (1) ALCAM/CD166 (1) Amino Acid Derivatives (2) Antibiotic (7) Antibody-Drug Conjugates (ADCs) (47) Antifolate (3) Apoptosis (18) Autophagy (2) Bacterial (13) Bcl-2 Family (1) Biochemical Assay Reagents (1) Btk (1) c-Met/HGFR (1) CD19 (1) CD22 (3) CD276/B7-H3 (1) CDK (1) Dipeptidyl Peptidase (1) DNA Alkylator/Crosslinker (19) DNA Methyltransferase (1) DNA/RNA Synthesis (5) Drug Metabolite (2) E3 Ligase Ligand-Linker Conjugates (3) EGFR (13) Epigenetic Reader Domain (1) Estrogen Receptor/ERR (3) FGFR (1) FLT3 (1) Glucocorticoid Receptor (7) Glucosidase (1) Glutathione Peroxidase (1) HSP (2) IGF-1R (1) Integrin (1) Interleukin Related (2) Isotope-Labeled Compounds (9) Kinesin (1) Mesothelin (1) Microtubule/Tubulin (74) Mitochondrial Metabolism (2) N-myristoyltransferase (1) NAMPT (6) Nectin-4 (1) Notch (1) Nucleoside Antimetabolite/Analog (1) Parasite (1) PD-1/PD-L1 (3) PI3K (1) PROTAC Linkers (211) PROTAC-Linker Conjugates for PAC (3) PROTACs (3) PSMA (1) Radionuclide-Drug Conjugates (RDCs) (1) STING (9) TAM Receptor (4) Telomerase (1) TNF Receptor (2) Toll-like Receptor (TLR) (2) Topoisomerase (67) TROP2 (6)
By Research Areas:	Cancer (1410) Cardiovascular Disease (3) Infection (19) Inflammation/Immunology (50) Metabolic Disease (1) Neurological Disease (2)
Click Chemistry:	ADC Synthesis (243) TCO (24) Labeling and Fluorescence Imaging (1) DBCO (69) PROTAC Synthesis (57) Azide (90) BCN (33) Tetrazine (49) Alkynes (55)

1468

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

313

Click Chemistry

Targets Recommended: ADC Cytotoxin ADC Antibody ADC Linker Drug-Linker Conjugates for ADC

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-164153

ADC Control Human IgG1-vcMMAE	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
ADC Control Human IgG1-vcMMAE is a humanized monoclonal antibody that is an isotype control of *ADC* human IgG1-vcMMAE and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is vcMMAE (HY-15575) .

HY-164154

ADC Control Human IgG1-vcMMAF	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
ADC Control Human IgG1-vcMMAF is a humanized monoclonal antibody that is an isotype control of *ADC* human IgG1-vcMMAF and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is MC-Val-Cit-PAB-MMAF (vcMMAF; HY-112786) .

HY-164152

ADC Control Human IgG1-Deruxtecan (DAR 4)	Antibody-Drug Conjugates (ADCs) Topoisomerase	Cancer
ADC Control Human IgG1-Deruxtecan (DAR 4) is a humanized monoclonal antibody that is an isotype control of *ADC* human IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .

HY-164152A

ADC Control Human IgG1-Deruxtecan (DAR 8)	Antibody-Drug Conjugates (ADCs) Topoisomerase	Cancer
ADC Control Human IgG1-Deruxtecan (DAR 8) is a humanized monoclonal antibody that is an isotype control of *ADC* human IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .

HY-P99742

Mitazalimab ADC-1013; JNJ-64457107	TNF Receptor	Cancer
Mitazalimab (ADC-1013; JNJ-64457107) is FcγR-dependent CD40 agonist with tumor-directed activity. Mitazalimab activates antigen-presenting cells, e.g. dendritic cells (DC), to initiate tumor-reactive T cells. Therefore, Mitazalimab induces tumor-specific T cells to infiltrate and kill tumors. Mitazalimab remodels the tumor-infiltrating myeloid microenvironment .

HY-P99349

Loncastuximab tesirine Loncastuximab tesirine-lpyl; ADCT-402	Antibody-Drug Conjugates (ADCs) Apoptosis	Cancer
Loncastuximab tesirine is a human cluster of differentiation 19 (CD19)-directed antibody-drug conjugate (ADC). Once bound to CD19 on the cell membrane, loncastuximab tesirine is rapidly internalised and triggers cell death. Loncastuximab tesirin induces cell apoptosis, it can be used for the research of diffuse large B-cell lymphoma .

HY-13631D

Dxd 5+ Cited Publications Exatecan derivative for ADC	Topoisomerase ADC Cytotoxin	Cancer
Dxd (Exatecan derivative for ADC) is a potent DNA topoisomerase I inhibitor, with an IC₅₀ of 0.31 μM, used as a conjugated drug of HER2-targeting ADC (DS-8201a).

HY-13631DS

Dxd-d5 Exatecan-d₅ derivative for ADC	Topoisomerase ADC Cytotoxin	Cancer
Dxd-d₅ is a deuterium labeled Dxd. Dxd is a potent DNA topoisomerase I inhibitor, with an IC50 of 0.31 μM, used as a conjugated drug of HER2-targeting ADC (DS-8201a) [1].

HY-P99734

Mipasetamab uzoptirine ADCT-601	TAM Receptor	Cancer
Mipasetamab uzoptirine (ADCT-601) is an AXL-targeted antibody-drug conjugates (ADCs). Mipasetamab uzoptirine consists of a humanized anti-AXL antibody, a cleavable linker and the potent pyrrolobenzodiazepine (PBD) dimer cytotoxin SG3199. Mipasetamab uzoptirine can be used for the research of cancers .

HY-164730

Epratuzumab Tesirine ADCT-602; hLL2-Cys-PBD	Antibody-Drug Conjugates (ADCs)	Cancer
Epratuzumab Tesirine (ADCT-602) is a novel CD22-targeted ADC. Epratuzumab Tesirine contains a PBD dimer and a payload SG3249 .

HY-145627

Ozuriftamab vedotin BA3021; Anti-ROR2 ADC; CAB-ROR2-ADC	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
Ozuriftamab vedotin (BA3021), an antibody-drug conjugate (ADC), is a conditionally active biologic (CAB) anti-receptor tyrosine kinase orphan receptor 2 (ROR2) humanized monoclonal antibody Ozuriftamab (HY-145626) conjugated to VcMMAE (HY-15575). Ozuriftamab vedotin has antitumor activities .

HY-155870

DL-01	Drug-Linker Conjugates for ADC	Cancer
DL-01 is a drug-linker conjugates for ADC that can be used for the synthesis of ADCs .

HY-164732

Fmoc-Lys(DOTA)-OH	ADC Linker	Cancer
Fmoc-Lys(DOTA)-OH is an ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-164731

Mal-PEG12-DOTA	ADC Linker	Cancer
Mal-PEG12-DOTA is an ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-160157

IM-2	Drug-Linker Conjugates for ADC	Cancer
IM-2 is an ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-144880

SC209	ADC Cytotoxin EGFR Drug Metabolite	Cancer
SC209, an ADC cytotoxin extracted from patent WO2021247798, is used in synthesis of anti-EGFR antibody-drug conjugate ADC. SC209 is the payload of STRO-002 .

HY-161022A

FL118-C3-O-C-amide-C-NH2 formate	ADC Linker	Cancer
FL118-C3-O-C-amide-C-NH2 format is an ADC linker for the synthesis of synthetic antibody conjugate active molecules (ADCs)..

HY-129360A

Ala-Ala-Asn-PAB TFA	ADC Linker	Cancer
Ala-Ala-Asn-PAB TFA is a peptide cleavable ADC linker for antibody-drug conjugates (ADCs) .

HY-156813

Fmoc-Val-Ala-aminomethyl acetate	ADC Linker	Cancer
Fmoc-Val-Ala-aminomethyl acetate (Compound 58b) is an ADC Linker, and can be used for synthesis of ADCs .

HY-139441

DM21	Drug-Linker Conjugates for ADC	Cancer
DM21 is a conjugate of a cleavable ADC agent and a linker (ADC linker) used in the synthesis of antibody-drug conjugates (ADCs) .

HY-126670

mDPR(Boc)-Val-Cit-PAB	ADC Linker	Cancer
mDPR(Boc)-Val-Cit-PAB is a cleavable ADC linker used as a linker for antibody-drug conjugates (ADC) .

HY-131833

Fmoc-Gly-Gly-Phe-OH	ADC Linker	Cancer
Fmoc-Gly-Gly-Phe-OH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-131451

Mc-Phe-Lys-PAB-MMAE	Drug-Linker Conjugates for ADC	Cancer
Mc-Phe-Lys-PAB-MMAE (Compound 2) is a drug-linker conjugate for ADC, and can be used for synthesis of ADCs .

HY-153196

Tetra-O-acetyl-β-D-galactopyranosyl-Ph-CH2-(4-nitrophenyl)carbonate-Fmoc	ADC Linker	Others
Tetra-O-acetyl-β-D-galactopyranosyl-Ph-CH2-(4-nitrophenyl)carbonate-Fmoc (Example 2.28.6) is an ADC linker that can be used to synthesize antibody-conjugated active molecules (ADCs) .

HY-400056

SC209 intermediate-2	ADC Cytotoxin	Cancer
SC209 intermediate-2 (Compound A9) is an intermediate of the ADC cytotoxin SC209 (HY-144880). SC209 intermediate-2 is an ADC Linker .

HY-W352966

Mal-PEG2-CH2COOH	ADC Linker	Cancer
Mal-PEG2-CH2COOH is an ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-47968

SC209 intermediate-1	ADC Linker	Cancer
SC209 intermediate-1 (Compound A7a) is an ADC linker. SC209 intermediate-1 can be used for synthesis of ADCs .

HY-114697

DSG Crosslinker Disuccinimidyl glutarate	ADC Linker	Inflammation/Immunology
DSG Crosslinker is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-118759

DSP Crosslinker 1 Publications Verification	ADC Linker	Inflammation/Immunology
DSP Crosslinker is a cleavable ADC linker, used in the synthesis of antibody-drug conjugates (ADCs) .

HY-160776

Diazido-methyltetrazine tri-arm	ADC Linker	Cancer
Diazido-methyltetrazine tri-arm is a polyvalent ADC linker and can be used for synthesis of ADCs .

HY-156687

GGFG-Eribulin	Drug-Linker Conjugates for ADC	Cancer
GGFG-Eribulin (Compound GGFG) is a Drug-Linker Conjugates for ADC. GGFG-Eribulin consists of the ADC Cytotoxin Eribulin (HY-13442) and a linker. GGFG-Eribulin can be used for synthesis of ADCs .

HY-128979B

Deruxtecan analog 2 monoTFA	Drug-Linker Conjugates for ADC	Cancer
Deruxtecan analog 2 (monoTFA) is a homolog of Deruxtecan (HY-13631E), a conjugate of the ADC toxin DX-8951 derivative (Dxd) with an ADC Linker .

HY-160790

β-Glu-PNP	ADC Linker	Cancer
β-Glu-PNP is an ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-20336

Mc-Val-Cit-PABC-PNP 2 Publications Verification Maleimidocaproyl-L-valine-L-citrulline-p-aminobenzyl alcohol p-nitrophenyl carbonate	ADC Linker	Others Inflammation/Immunology Cancer
Mc-Val-Cit-PABC-PNP is a cathepsin cleavable linker for antibody-drug conjugates (ADCs) which couples the antibody element to the effecting compound. Mc-Val-Cit-PABC-PNP can be used in the synthesis of ADCs .

HY-157284

Cys-mc-MMAE	Drug-Linker Conjugates for ADC	Cancer
Cys-mc-MMAE is a Drug-Linker Conjugates for ADC, and consists of Monomethyl auristatin E (HY-15162) and a linker. Cys-mc-MMAE can be used for synthesis of ADCs .

HY-117409

Aminoethyl-SS-ethylalcohol	ADC Linker	Cancer
Aminoethyl-SS-ethylalcohol is a glutathione cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-135418

Fmoc-Asp-NH2	ADC Linker	Cancer
Fmoc-Asp-NH2 is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

HY-158135

Val-Cit-PAB-DEA-COOH	ADC Linker	Cancer
Val-Cit-PAB-DEA-COOH (compound 17) is an ADC linker that can be used in the synthesis of *ADCs* .

HY-156617

Cyclopropaneacetamide-Exatecan	ADC Cytotoxin Topoisomerase	Cancer
Cyclopropaneacetamide-Exatecan (Compound 2-A) is an ADC Cytotoxin and an Exatecan analogue. Cyclopropaneacetamide-Exatecan can be used in the synthesis of *ADC* such as anti-B7H3 antibody-Exatecan analogue conjugate (compound ADC-2) .

HY-126665A

DMEA-PNU-159682 dichloroacetate	ADC Cytotoxin	Cancer
DMEA-PNU-159682 (molecule D12) dichloroacetate is an ADC cytotoxin molecule including metabolites of nemorubicin (MMDX) from liver microsomes and a potent ADCs cytotoxin PNU-159682 .

HY-164146

BCN-HS-PEG2(vcPABC-MMAE)2	ADC Linker	Cancer
BCN-HS-PEG2(vcPABC-MMAE)2 is an ADC linker, and can be used for the synthesis of ADCs .

HY-41541

Tetraethylene glycol monotosylate Tos-PEG4	ADC Linker PROTAC Linkers	Cancer
Tetraethylene glycol monotosylate is a cleavable and acylhydrazone-based ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . Tetraethylene glycol monotosylate also can be used as a PROTAC linker that can be used in the synthesis of PROTACs.

HY-131156

Mal-PEG2-Val-Cit-PABA-PNP	ADC Linker	Cancer
Mal-PEG2-Val-Cit-PABA-PNP is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-140144

Mal-PEG1-Val-Cit-PAB-PNP	ADC Linker	Cancer
Mal-PEG1-Val-Cit-PAB-PNP is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-148463

MP-Ala-Ala-PAB	ADC Linker	Cancer
MP-Ala-Ala-PAB is a cleavable ADC linker. Fmoc-Ala-Ala-PAB can be used in the synthesis of antibody-drug conjugates (ADCs) .

HY-148461

Mal-VC-PAB-PNP	ADC Linker	Cancer
Mal-VC-PAB-PNP is a cleavable ADC linker. Mal-VC-PAB-PNP can be used in the synthesis of antibody-drug conjugates (ADCs) .

HY-148462

Fmoc-Ala-Ala-PAB	ADC Linker	Cancer
Fmoc-Ala-Ala-PAB is a cleavable ADC linker. Fmoc-Ala-Ala-PAB can be used in the synthesis of antibody-drug conjugates (ADCs) .

HY-148464

MC-Ala-Ala-PAB	ADC Linker	Cancer
MC-Ala-Ala-PAB is a cleavable ADC linker. Fmoc-Ala-Ala-PAB can be used in the synthesis of antibody-drug conjugates (ADCs) .

HY-131833A

Fmoc-Gly-Gly-D-Phe-OH	ADC Linker	Cancer
Fmoc-Gly-Gly-D-Phe-OH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-Gly-Gly-D-Phe-OH is the D-isomer of Fmoc-Gly-Gly-Phe-OH (HY-131833).

HY-131833G

Fmoc-Gly-Gly-Phe-OH	ADC Linker	Cancer
Fmoc-Gly-Gly-Phe-OH GMP is a GMP grade Fmoc-Gly-Gly-Phe-OH (HY-131833). Fmoc-Gly-Gly-Phe-OH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-P99742

Mitazalimab ADC-1013; JNJ-64457107	Classification of Application Fields Disease Research Fields Cancer	TNF Receptor
Mitazalimab (ADC-1013; JNJ-64457107) is FcγR-dependent CD40 agonist with tumor-directed activity. Mitazalimab activates antigen-presenting cells, e.g. dendritic cells (DC), to initiate tumor-reactive T cells. Therefore, Mitazalimab induces tumor-specific T cells to infiltrate and kill tumors. Mitazalimab remodels the tumor-infiltrating myeloid microenvironment .

HY-117371

Hemiasterlin (-)-Hemiasterlin; Milnamide B	Alkaloids Structural Classification Classification of Application Fields Animals Marine natural products Sponge Disease Research Fields Indole Alkaloids Cancer	ADC Cytotoxin
Hemiasterlin ((-)-Hemiasterlin) is an antimitotic marine natural product with potent anticancer effcts. Hemiasterlin can be used as a cytotoxic payload (ADC Cytotoxin) in antibody-drug conjugates (ADCs) .

HY-W007324

Maleimide	Alkaloids Microorganisms Pyrrole Alkaloids Other Alkaloids Source classification Endogenous metabolite Disease Research Fields Cancer	ADC Linker
Maleimide can be used for production of antibody-drug conjugate (ADC) which is used in cancer research. Maleimide also be leveraged for the preparation of fluorogenic probe, which is mainly used for the specific detection of thiol analytes .

HY-P9921A

Trastuzumab emtansine (solution) 2 Publications Verification Ado-Trastuzumab emtansine (solution) ; PRO132365 (solution) ; T-DM 1 (solution)	Classification of Application Fields Disease Research Fields Cancer	Antibody-Drug Conjugates (ADCs) EGFR
Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine). Trastuzumab emtansine can be used for the research of advanced breast cancer .

HY-P99352

Anetumab Anti-MSLN Antibody	Classification of Application Fields Disease Research Fields Cancer	Mesothelin
Anetumab (Anti-MSLN Antibody) is an anti-mesothelin (MSLN) antibody. MSLN is a tumor-associated antigen. Anetumab can be used to synthesis Anetumab ravtansine, a MSLN-targeting antibody-drug conjugate (ADC). Anetumab can be used for the research of malignant tumor .

HY-P99225

Mirvetuximab M9346A	Classification of Application Fields Disease Research Fields Cancer	Antifolate
Mirvetuximab (M9346A) is an anti-FOLR1 (folate receptor 1) monoclonal antibody. Mirvetuximab is the antibody moiety of novel folate receptor alpha (FRα)-targeting ADC (Mirvetuximab soravtansine). Mirvetuximab soravtansine can be used in ovarian and other FRα-positive cancer research .

HY-P99016

Enfortumab	Classification of Application Fields Disease Research Fields Cancer	ADC Antibody Nectin-4
Enfortumab is a humanized derived anti-Nectin-4 antibody that can be conjugated with the highly efficient microtubule disruptor MMAE (HY-15162) to generate the antibody drug conjugate (ADC) Enfortumab vedotin (HY-P99016A). Enfortumab can be used for the study of locally advanced and metastatic urothelial carcinoma .

HY-P99043

Rovalpituzumab	Classification of Application Fields Disease Research Fields Cancer	Notch
Rovalpituzumab is a humanized monoclonal antibody against delta-like protein 3 (DLL3). Rovalpituzumab can be used in the synthesis of antibody-drug conjugate (ADC), Rovalpituzumab Tesirine . Rovalpituzumab has activity against small cell lung cancer (SCLC) .

HY-P99734

Mipasetamab uzoptirine ADCT-601	Classification of Application Fields Disease Research Fields Cancer	TAM Receptor
Mipasetamab uzoptirine (ADCT-601) is an AXL-targeted antibody-drug conjugates (ADCs). Mipasetamab uzoptirine consists of a humanized anti-AXL antibody, a cleavable linker and the potent pyrrolobenzodiazepine (PBD) dimer cytotoxin SG3199. Mipasetamab uzoptirine can be used for the research of cancers .

HY-19829

Sandramycin	Infection Structural Classification Microorganisms Classification of Application Fields Antibiotics Source classification Antibacterial Disease Research Anticancer Disease Research Fields Other Antibiotics	ADC Cytotoxin Bacterial Antibiotic
Sandramycin ia a cyclic depsipeptide antibiotic isolated from cultured broth of a Nocardioides sp. Sandramycin is also a DNA intercalator that potently binds DNA and is an ADC cytotoxin. Sandramycin is active against Gram-positive bacteria and has potent antitumor activity .

HY-P99205

Glembatumumab	Classification of Application Fields Disease Research Fields Cancer	ADC Antibody
Glembatumumab is a fully human IgG2 monoclonal antibody directed against the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. Glembatumumab can be coupled to the microtubule inhibitor monomethyl auristatin E to form glembatumumab vedotin. Glembatumumab vedotin is an antibody-agent coupling (ADC) with antitumor activity .

HY-P99054

Tusamitamab	Classification of Application Fields Disease Research Fields Cancer	Others
Tusamitamab is an IgG1 monoclonal antibody that targets CEACAM5. Tusamitamab can be used to synthesize Tusamitamab ravtansine (SAR408701), which is a first-in-class humanized antibody-drug conjugate (ADC) that combines Tusamitamab and DM4 (a potent maytansine derivative) .

HY-131081

γ-Amanitin	Structural Classification Alkaloids Microorganisms Classification of Application Fields Other Alkaloids Source classification Disease Research Fields Cancer	DNA/RNA Synthesis ADC Cytotoxin
γ-Amanitin an ADC cytotoxin and isolated from the mushroom. γ-Amanitin inhibits RNA polymerase II and disrupts synthesis of mRNA. γ-Amanitin shows similar effects to α-Amanitin and β-Amanitin. γ-Amanitin competitively binds to monoclonal antibody (mAb), with an IC₅₀ of 163.1 ng/mL .

HY-P99843

Datopotamab	Classification of Application Fields Disease Research Fields Cancer	TROP2 ADC Antibody
Datopotamab (CDP7657) is a humanized anti trophoblast cell surface antigen 2 (TROP2) antibody. Datopotamab can generate antibody drug conjugates (ADC) (HY-141598) with DNA topoisomerase I inhibitor Deruxtecan (HY-13631E). Datopotamab can be used in the study of triple negative breast cancer and non-small cell lung cancer .

HY-P99612

Farletuzumab ecteribulin MORAb-202	Classification of Application Fields Disease Research Fields Cancer	Antibody-Drug Conjugates (ADCs)
Farletuzumab ecteribulin (MORAb-202) is an antibody-drug conjugate (ADC), consisting of the humanized anti-human folate receptor alpha (FRA) antibody Farletuzumab (HY-P99153) conjugated via reduced interchain disulfide bonds to Mal-PEG2-Val-Cit-PAB-eribulin. Farletuzumab ecteribulin has a agent-to-antibody ratio of 4.0. Farletuzumab ecteribulin is highly cytotoxic to FRA-positive cells in vitro. Farletuzumab ecteribulin has potent antitumor activity.

HY-W034595

Eicosanedioic acid	Microorganisms Source classification	ADC Linker PROTAC Linkers
Eicosanedioic acid is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Eicosanedioic acid is also a alkyl chain-based PROTAC linker that can be used in the synthesis

HY-W034918

Docosanedioic acid	Structural Classification other families Classification of Application Fields Ketones, Aldehydes, Acids Source classification Plants Disease Research Fields Cancer	ADC Linker PROTAC Linkers
Docosanedioic acid is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Docosanedioic acid is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.

HY-P990027

Izeltabart	Classification of Application Fields Disease Research Fields Cancer	ADC Antibody
Izeltabart is a high-affinity humanized antibody targeting ADAM9. Izeltabart can be used as ADC Antibody for site-specific conjugation with Maytansinoid-based DM21-C (a Drug-Linker Conjugates for ADC), to synthesize IMGC936 (Antibody-Drug Conjugates (ADCs)) with strong anti-cancer activity. DM21-C is composed of Maytansinoid (microtubule inhibitor) and a stable tripeptide linker. IMGC936 exhibits cytotoxicity against ADAM9-positive human tumor cell lines and potent antitumor activity in xenograft tumor models .

HY-P99329

Vadastuximab Anti-Human CD33 Recombinant Antibody	Classification of Application Fields Disease Research Fields Cancer	Others
Vadastuximab is a humanized monoclonal antibody targeting CD33. Vadastuximab can be used to synthesize an ADC compound, Vadastuximab talirine .

HY-N2348

Tubulysin D	Structural Classification Natural Products Microorganisms Classification of Application Fields Source classification Disease Research Fields Cancer	ADC Cytotoxin Microtubule/Tubulin
Tubulysin D is a highly cytotoxic anti-microtubule toxin (anti-microtubule toxins) that is synthesized as an ADC cytotoxin (ADC Cytotoxin). Tubulysin D can be isolated from the myxobacteria Archangium geophyra and Angiococcus disciformis. Tubulysin D displays extremely potent cytotoxic activity in mammalian cells, including multidrug-resistant cell lines, with IC₅₀ values in the low nanomolar range. Tubulysin D inhibits microtubule/Tubulin polymerization and leads to cell cycle arrest and apoptosis .

HY-N2346

Tubulysin E	Structural Classification Natural Products Microorganisms Classification of Application Fields Source classification Disease Research Fields Cancer	ADC Cytotoxin Microtubule/Tubulin
Tubulysin E is a highly cytotoxic anti-microtubule toxin (anti-microtubule toxins) that is synthesized as an ADC cytotoxin (ADC Cytotoxin). Tubulysin E can be isolated from the myxobacteria Archangium geophyra and Angiococcus disciformis. Tubulysin E displays extremely potent cytotoxic activity in mammalian cells, including multidrug-resistant cell lines, with IC₅₀ values in the low nanomolar range. Tubulysin E inhibits microtubule/Tubulin polymerization and leads to cell cycle arrest and apoptosis .

HY-N2347

Tubulysin C	Structural Classification Natural Products Monophenols Microorganisms Classification of Application Fields Source classification Phenols Disease Research Fields Cancer	ADC Cytotoxin Microtubule/Tubulin
Tubulysin C is a highly cytotoxic anti-microtubule toxin (anti-microtubule toxins) that is synthesized as an ADC cytotoxin (ADC Cytotoxin). Tubulysin C can be isolated from the myxobacteria Archangium geophyra and Angiococcus disciformis. Tubulysin C displays extremely potent cytotoxic activity in mammalian cells, including multidrug-resistant cell lines, with IC₅₀ values in the low nanomolar range. Tubulysin C inhibits microtubule/Tubulin polymerization and leads to cell cycle arrest and apoptosis .

HY-N7049

Tubulysin F	Structural Classification Natural Products Microorganisms Classification of Application Fields Source classification Disease Research Fields Cancer	ADC Cytotoxin Microtubule/Tubulin
Tubulysin F is a highly cytotoxic anti-microtubule toxin (anti-microtubule toxins) that is synthesized as an ADC cytotoxin (ADC Cytotoxin). Tubulysin F can be isolated from the myxobacteria Archangium geophyra and Angiococcus disciformis. Tubulysin F displays extremely potent cytotoxic activity in mammalian cells, including multidrug-resistant cell lines, with IC₅₀ values in the low nanomolar range. Tubulysin F inhibits microtubule/Tubulin polymerization and leads to cell cycle arrest and apoptosis .

HY-N7050

Tubulysin G	Structural Classification Monophenols Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Source classification Phenols Disease Research Fields Cancer	ADC Cytotoxin Microtubule/Tubulin
Tubulysin G is a highly cytotoxic anti-microtubule toxin (anti-microtubule toxins) that is synthesized as an ADC cytotoxin (ADC Cytotoxin). Tubulysin G can be isolated from the myxobacteria Archangium geophyra and Angiococcus disciformis. Tubulysin G displays extremely potent cytotoxic activity in mammalian cells, including multidrug-resistant cell lines, with IC₅₀ values in the low nanomolar range. Tubulysin G inhibits microtubule/tubulin polymerization and leads to cell cycle arrest and apoptosis .

HY-N7051

Tubulysin H	Structural Classification Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Source classification Disease Research Fields Cancer	ADC Cytotoxin Microtubule/Tubulin
Tubulysin H is a highly cytotoxic anti-microtubule toxin (anti-microtubule toxins) that is synthesized as an ADC cytotoxin (ADC Cytotoxin). Tubulysin H can be isolated from the myxobacteria Archangium geophyra and Angiococcus disciformis. Tubulysin H displays extremely potent cytotoxic activity in mammalian cells, including multidrug-resistant cell lines, with IC₅₀ values in the low nanomolar range. Tubulysin H inhibits microtubule/tubulin polymerization and leads to cell cycle arrest and apoptosis .

HY-N7052

Tubulysin I	Structural Classification Monophenols Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Source classification Phenols Disease Research Fields Cancer	ADC Cytotoxin Microtubule/Tubulin
Tubulysin I is a highly cytotoxic anti-microtubule toxin (anti-microtubule toxins) that is synthesized as an ADC cytotoxin (ADC Cytotoxin). Tubulysin I can be isolated from the myxobacteria Archangium geophyra and Angiococcus disciformis. Tubulysin I displays extremely potent cytotoxic activity in mammalian cells, including multidrug-resistant cell lines, with IC₅₀ values in the low nanomolar range. Tubulysin I inhibits microtubule/tubulin polymerization and leads to cell cycle arrest and apoptosis .

HY-N7053

Tubulysin M	Structural Classification Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Source classification Disease Research Fields Cancer	ADC Cytotoxin Microtubule/Tubulin
Tubulysin M is a highly cytotoxic anti-microtubule toxin (anti-microtubule toxins) that is synthesized as an ADC cytotoxin (ADC Cytotoxin). Tubulysin M can be isolated from the myxobacteria Archangium geophyra and Angiococcus disciformis. Tubulysin M displays extremely potent cytotoxic activity in mammalian cells, including multidrug-resistant cell lines, with IC₅₀ values in the low nanomolar range. Tubulysin M inhibits microtubule/tubulin polymerization and leads to cell cycle arrest and apoptosis .

HY-P9980

Belantamab GSK2857914	Classification of Application Fields Disease Research Fields Cancer	TNF Receptor ADC Antibody
Belantamab (GSK2857914) is a humanised IgG1 anti-BCMA (TNFRSF17) monoclonal antibody. Belantamab can be used in the synthesis of antibody-drug conjugate (ADC), Belantamab mafodotin .

HY-P99854

Disitamab RC48-0	Classification of Application Fields Disease Research Fields Cancer	EGFR ADC Antibody
Disitamab (RC48-0) is a humanized monoclonal antibody targeting HER2. Disitamab can be used in the synthesis of antibody-drug conjugates (ADCs), Disitamab vedotin (Disitamab vedotin (HY-P9985)) .

HY-P99372

Lorvotuzumab Anti-NCAM1/ CD56 Reference Antibody (lorvotuzumab)	Classification of Application Fields Disease Research Fields Cancer	ADC Antibody
Lorvotuzumab (Anti-NCAM1/CD56 Reference Antibody (lorvotuzumab)) is a humanized monoclonal antibody that binds CD56 (NCAM1). Lorvotuzumab can be used to synthesize an ADC compound, Lorvotuzumab mertansine .

HY-12457

Rachelmycin CC-1065; NSC 298223	Structural Classification Classification of Application Fields Source classification Disease Research Other Antibiotics Infection Monophenols Microorganisms Antibiotics Phenols Anticancer Disease Research Fields Cancer	Antibiotic DNA/RNA Synthesis
Rachelmycin (CC-1065) is an antitumor antibiotic and a DNA-alkylating agent. Rachelmycin has cytotoxic potency that can be used as a cytotoxin to synthesis ADC. Rachelmycin effectively inhibits DNA synthesis. Rachelmycin can be used for cancer and infection research .

HY-P99101

Vobramitamab AEX-4089	Classification of Application Fields Disease Research Fields Cancer	ADC Antibody
Vobramitamab is a humanized B7-H3 monoclonal antibody (mAb). Vobramitamab conjugated with prodrug seco-DUBA (HY-132180A) via a cleavable linker, to form antibody-drug conjugate (ADC), the MGC018. .

HY-P99234

Pivekimab	Classification of Application Fields Disease Research Fields Cancer	Interleukin Related ADC Antibody
Pivekimab is a human IgG1 monoclonal antibody that targets interleukin-3 (IL-3) and CD123. Pivekimab is used to synthesize pivekimab sunirine, a CD123-directed antibody-active molecule conjugate (ADC). Pivekimab is used in the study of blastic plasmacytoid dendritic cell neoplasm (BPDCN) .

HY-P99682

Ladiratuzumab hLIV22	Classification of Application Fields Disease Research Fields Cancer	Others
Ladiratuzumab (hLIV22) is an anti-LIV-1/ZIP6 humanized monoclonal antibody. Ladiratuzumab, conjugated with the microtubule disrupting agent, MMAE (HY-15162) to compose SGN-LIV1A, an antibody-drug conjugate (ADC). Ladiratuzumab can be used for research of breast cancer .

HY-106338

Polyketomycin	Infection Quinones Structural Classification Microorganisms Classification of Application Fields Source classification Phenols Polyphenols Naphthalene Quinones Disease Research Fields	Bacterial ADC Cytotoxin Parasite
Polyketomycin is a tetracyclic quinone glycoside antibiotic isolated from Streptomyces sp. or Streptomyces diastatochromogenes. Polyketomycin inhibits growth of Gram-positive bacteria, and its MIC values is less than 0.2 µg/mL. Polyketomycin has antibacterial, anticancer, antimalarial activities .

HY-P99971

Gemtuzumab	Classification of Application Fields Disease Research Fields Cancer	ADC Antibody
Gemtuzumab is a monoclonal IgG4-κ antibody targeting CD33 antigen, which present on leukemic myeloblasts of acute myeloid leukemia (AML). Gemtuzumab can be used for synthesis of antibody-drug conjugate *(ADC)*, Gemtuzumab ozogamicin (HY-109539). Gemtuzumab ozogamicin consists of a cytotoxic derivative of Calicheamicin (a cytotoxic antibiotic), and a monoclonal antibody. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia .

HY-114936

Piericidin A 1 Publications Verification AR-054	Structural Classification Neurological Disease Classification of Application Fields Source classification Anti-parasitic Antibacterial Disease Research Other Antibiotics Infection Microorganisms Antibiotics Anticancer Disease Research Fields	Bacterial ADC Cytotoxin Antibiotic Mitochondrial Metabolism
Piericidin A (AR-054) is a natural mitochondrial NADH-ubiquinone oxidoreductase (complex I) inhibitor. Piericidin A is a potent neurotoxin and inhibits mitochondrial respiration by disrupting the electron transport system through its action on NADH-ubiquinone reductase. Piericidin A is also a potential quorum-sensing inhibitor that suppresses the expression of the virulence genes of Erwinia carotovora subsp. atroseptica (Eca). Piericidin A is an ADC cytotoxin and has anti-bacterial, anticancer, insecticidal activity .

HY-P99045

Sacituzumab	Classification of Application Fields Disease Research Fields Cancer	ADC Antibody TROP2
Sacituzumab is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab is used for the synthesis of antibody-drug conjugates (ADC) drugs. Antibody-drug conjugates with sacituzumab (sacituzumab govitecan) (HY-132254) targeting TROP-2 have been approved for the field of triple-negative breast cancer .

Cat. No.	Product Name	Chemical Structure

HY-13631DS

Dxd-d5
Dxd-d₅ is a deuterium labeled Dxd. Dxd is a potent DNA topoisomerase I inhibitor, with an IC50 of 0.31 μM, used as a conjugated drug of HER2-targeting ADC (DS-8201a) [1].

HY-145989S

Aminobenzenesulfonic auristatin E-d8
Aminobenzenesulfonic auristatin E-d₈ is the deuterium labeled Aminobenzenesulfonic auristatin E. Aminobenzenesulfonic auristatin E is a drug-linker conjugate for ADC. Aminobenzenesulfonic auristatin E has potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic[1][2].

HY-116852S

Thiocolchicine-d3

Thiocolchicine-d₃ is deuterium labeled Thiocolchicine. Thiocolchicine, a derivative modified in the C Ring of Colchicine (HY-16569) with enhanced biological properties. Thiocolchicine is a potent inhibitor of tubulin polymerization (IC50=2.5 µM) and competitively binds to tubulin with a Ki of 0.7 µM. Thiocolchicine induces cell apoptosis[1][2]. Thiocolchicine can be used as an ADC cytotoxin in ADC technology.

HY-161022S1

FL118-C3-O-C-amide-C-NH2-d5 formate
FL118-C3-O-C-amide-C-NH2-d5 formate is a deuterium labeled FL118-C3-O-C-amide-C-NH2 formate. FL118-C3-O-C-amide-C-NH2 formate is an ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-156756S

7-Hydroxymethyl-10,11-MDCPT-d5
7-Hydroxymethyl-10,11-MDCPT-d₅ is deuterium labeled 7-Hydroxymethyl-10,11-MDCPT, which is a is a payload that can be used for *ADC* synthesis .

HY-15575S

VcMMAE-d8
VcMMAE-d8 is an isotope of VcMMAE (HY-15575). VcMMAE-d8 is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc) .

HY-114816S

N-butyryl-L-Homoserine lactone-d5

N-butyryl-L-Homoserine lactone-d₅ is the deuterium labeled N-Butanoyl-L-homoserine lactone. N-Butanoyl-L-homoserine lactone (C4-HSL) is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). N-Butanoyl-L-homoserine lactone has antibacterial activity and is used in antibacterial biofilm[1]. N-Butanoyl-L-homoserine lactone aptamers blocks qurom sensing and inhibits biofilm formation in Pseudomonas aeruginosa[2][3].

HY-13631ES4

Deruxtecan-d5
Deruxtecan-d₅ is deuterium labeled Deruxtecan (HY-13631E). Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.

HY-13631ES

Deruxtecan-d4
Deruxtecan-d₄ is deuterium labeled Deruxtecan (HY-13631E). Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.

HY-79369S

Succinic anhydride-d4
Succinic anhydride-d₄ is the deuterium labeled Succinic anhydride. Succinic anhydride is a cyclic anhydride and a nonclaevable ADC linker extracted from patent WO2009064913A1. Succinic anhydride can react with compound 4 of the patent to link the proagent to an amine or hydroxy 1 group of a targeting polypeptide[1].

HY-79369S1

Succinic anhydride-13C2
Succinic anhydride- ¹³C₂ is the ¹³C labeled Succinic anhydride[1]. Succinic anhydride is a cyclic anhydride and a nonclaevable ADC linker extracted from patent WO2009064913A1. Succinic anhydride can react with compound 4 of the patent to link the proagent to an amine or hydroxy 1 group of a targeting polypeptide[2].

HY-15583S

Auristatin F-d8
Auristatin F-d₈ is deuterium labeled Auristatin F (HY-15583). Auristatin F is a potent cytotoxin in antibo-conjugated agents and an analogue of MMAF. Auristatin F is a potent microtubule inhibitor and vascular damaging agent (VDA). Auristatin F inhibits cell division by preventing tubulin aggregation.Auristatin F can be used in antibody-drug conjugates (ADC) .

HY-145397S

(4-NH2)-Exatecan-d5
(4-NH2)-Exatecan-d5 is a deuterated labeled (4-NH2)-Exatecan . (4-NH2)-Exatecan (compound A), a topoisomerase inhibitor, is a derivative of Exatecan. (4-NH2)-Exatecan can be used in the synthesis of antibody-drug conjugates (ADCs) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks